Who owns LIGAND PHARMACEUTICALS INC (LGND)? Elite investor 13F holders
3 tracked elite investors reported holding LIGAND PHARMACEUTICALS INC as of 2026-06-30, including D.E. Shaw, Gotham Asset Management, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | LIGAND PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 17863826.00 USD | 56515.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | LIGAND PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1141085.00 USD | 3610.000000 | Shares | reduce | Original filing |
| Ancora Advisors / Ancora Holdings | LIGAND PHARMACEUTICALS INC ROC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 16.00 USD | 12000.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.